Stryker (NYSE:SYK) Updates FY 2025 Earnings Guidance

Stryker (NYSE:SYK) updated its FY 2025 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 13.450-13.700 for the period, compared to the consensus estimate of 13.510. The company issued revenue guidance of -.

Wall Street Analyst Weigh In

SYK has been the subject of several recent research reports. UBS Group increased their target price on shares of Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a research note on Wednesday, October 30th. BTIG Research raised their price objective on Stryker from $383.00 to $394.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. Wells Fargo & Company boosted their target price on Stryker from $427.00 to $435.00 and gave the stock an “overweight” rating in a research report on Wednesday. Royal Bank of Canada increased their price target on Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a research report on Wednesday. Finally, Barclays boosted their price objective on Stryker from $402.00 to $418.00 and gave the stock an “overweight” rating in a report on Thursday, October 31st. Five analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $413.45.

Stryker Stock Performance

Shares of SYK opened at $390.98 on Thursday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22. Stryker has a one year low of $314.05 and a one year high of $406.19. The company’s fifty day moving average price is $376.44 and its 200 day moving average price is $361.98. The company has a market capitalization of $149.05 billion, a PE ratio of 41.91, a price-to-earnings-growth ratio of 2.68 and a beta of 0.95.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 16.34% and a return on equity of 23.07%. During the same period in the prior year, the business earned $3.46 EPS. As a group, analysts expect that Stryker will post 12.06 earnings per share for the current year.

Stryker Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be given a dividend of $0.84 per share. The ex-dividend date of this dividend is Tuesday, December 31st. This is a boost from Stryker’s previous quarterly dividend of $0.80. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.86%. Stryker’s payout ratio is currently 36.01%.

Insider Activity

In other news, CEO Kevin Lobo sold 57,313 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the transaction, the chief executive officer now directly owns 100,027 shares of the company’s stock, valued at $36,879,954.90. The trade was a 36.43 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 5.90% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.